Corporate ProfileG1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer. G1’s two clinical assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of targets for anti-cancer therapeutics. These two product candidates have the potential to treat nearly all forms of cancer and be administered in combination with most conventional and emerging cancer therapies. In addition, G1 has exclusively in-licensed G1T48, a potential first/best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of a particular type of breast cancer. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates.
Stock Information

GTHX (Common Stock)


 0.43 (2.56%)


05/26/17 3:59 p.m. ET

Stock chart for: GTHX.O.  Currently trading at $17.24 with a 52 week high of $17.00 and a 52 week low of $13.35.
Recent NewsMore >>
05/23/17G1 Therapeutics Announces Closing of Initial Public OfferingPrinter Friendly Version
05/16/17G1 Therapeutics Announces Pricing of Initial Public OfferingPrinter Friendly Version
05/08/17G1 Therapeutics Announces Launch of Initial Public OfferingPrinter Friendly Version
03/29/17G1 Therapeutics Announces Presentations at the 2017 American Association for Cancer Research Annual MeetingPrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.